Hims (HIMS) Jumps 8.6% as Firm Still Open to Work With Novo

We recently published Market on Mute? Not for These 10 Stocks With Surprising Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is one of Monday’s top performers.

Hims & Hers bounced back by 8.64 percent on Monday to close at $52.03 following announcements that it remains open to working with Novo Nordisk in the future despite the termination of its earlier partnership.

Novo Nordisk, maker of blockbuster drugs Wegovy and Ozempic, terminated its deal with Hims & Hers Health, Inc. (NYSE:HIMS) in June over allegations that the latter failed to adhere to federal laws that prohibit mass sales of compounded drugs under the false guise of “personalization.”

Hims & Hers Health, Inc. (NYSE:HIMS) has been selling knockoff versions of the drugs for years amid strong demand, but was this year ordered by the Food and Drug Administration (FDA) to stop due to a now sufficient supply.

Hims (HIMS) Jumps 8.6% as Firm Still Open to Work With Novo

A nurse in a telehealth platform talking with a patient on video call for consultation.

After the termination, Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum said he was upset that Novo Nordisk felt the pressure over the knockoff version, but said that there was “no way in hell we’re going to cave on that.”

Based on its historical reporting dates, Hims & Hers Health, Inc. (NYSE:HIMS) will report its earnings results for the second quarter in the first week of August 2025.

While we acknowledge the risk and potential of HIMS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than HIMS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.